Eguavoen Amenze, Larson Heidi J, Chinye-Nwoko Fejiro, Ojeniyi Toluwanimi
Programs Department, Nigeria Solidarity Support Fund, Lagos, Nigeria.
Department of Infectious Disease and Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom.
J Public Health Afr. 2023 May 4;14(5):2290. doi: 10.4081/jphia.2023.2290. eCollection 2023 Apr 30.
By May 30, 2022, there were 526,182,662 confirmed COVID- 19 cases and 6,286,057 deaths globally; of which Nigeria had recorded 256,028 confirmed cases and 3143 deaths. By the same time, Nigeria had received a total of 93.9 million doses of the COVID-19 vaccine, enough to vaccinate 25% of the population; however, only 27.4 million people (13.3% of the population) had received at least one dose of the vaccine. This article examines available evidence on COVID-19 vaccine hesitancy in Nigeria and makes recommendations for improving its uptake. Major causes of COVID-19 vaccine hesitancy identified in Nigeria were concerns around vaccine efficacy and safety, disbelief in the existence and severity of the disease, and distrust of the government. To reduce COVID-19 vaccine hesitancy and improve vaccine coverage in Nigeria, mapping vaccine acceptance and hesitancy across geographies and demographics is needed, as well as increased stakeholder communication, and effective community engagement.
截至2022年5月30日,全球累计确诊新冠肺炎病例526,182,662例,死亡6,286,057例;其中尼日利亚累计确诊256,028例,死亡3143例。同一时期,尼日利亚共收到9390万剂新冠疫苗,足以覆盖25%的人口;然而,只有2740万人(占人口的13.3%)接种了至少一剂疫苗。本文研究了尼日利亚对新冠疫苗犹豫的现有证据,并提出了提高疫苗接种率的建议。在尼日利亚,导致对新冠疫苗犹豫的主要原因包括对疫苗效力和安全性的担忧、对疾病存在及严重性的怀疑以及对政府的不信任。为减少尼日利亚对新冠疫苗的犹豫并提高疫苗接种率,需要对不同地区和人群的疫苗接受度和犹豫情况进行摸底,加强利益相关方沟通,并开展有效的社区参与活动。